References
- Ytterberg S, Bhatt D, Mikuls T, et al. Safety and efficacy of tofacitinib vs TNF inhibitors in RA patients aged 50 years or older with one or more cardiovascular risks: Results from a Phase 3b/4 randomized safety trial [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Charles-Schoeman C, Buch M, Dougados M, et al. Risk factors for major adverse cardiovascular events in patients aged ≥50 years with RA and ≥1 additional cardiovascular risk factor: Results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Curtis J, Yamaoka K, Chen Y, et al. Malignancies in patients aged ≥50 years with RA and ≥1 additional cardiovascular risk factor: Results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Charles-Schoeman C, Fleischmann R, Mysler E, et al. The risk of venous thromboembolic events in patients with RA aged ≥ 50 years with ≥ 1 cardiovascular risk factor: Results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors Arthritis Rheumatol. 2021;73(suppl 10).
- Hahn J, Cook N, Alexander A, et al. Vitamin D and marine n-3 fatty acid supplementation and prevention of autoimmune disease in the VITAL randomized controlled trial Arthritis Rheumatol. 2021;73(suppl 10).
- Rech J, Ostergaard M, Tascilar K, et al. Abatacept reverses subclinical arthritis in patients with high-risk to develop rheumatoid arthritis—Results from the randomized, placebo-controlled ARIAA study in RA-at risk patients Arthritis Rheumatol. 2021;73(suppl 10).
- Colmegna I, Useche M, Rampakakis E, et al. COVID-19 vaccine in immunosuppressed adults with autoimmune diseases [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Mahil S, Bechman K, Raharja A, et al. Humoral and cellular immune responses to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: A cohort study [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Bonelli M, Mrak D, Tobudic S, et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: A randomized controlled trial [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Solomon J, Woodhead F, Danoff S, et al. A randomized, double-blinded, placebo-controlled, phase 2 study of safety, tolerability and efficacy of pirfenidone in patients with rheumatoid arthritis interstitial lung disease [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Najm A, Sarda S, Toro M, et al. B cells repertoire repartition predicts response to methotrexate at 6 and 12 months in naïve RA: A machine learning driven approach [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
